TABLE 1. Clinical trials identified at Clinicaltrials.gov related to drug repositioning for COVID-19 treatment.
Intervention |
Clinical condition |
Sponsor |
N° test / Status |
Beginning / Estimated end |
Phase |
|---|---|---|---|---|---|
Hydroxychloroquine |
30 participants with pneumonia caused by 2019-nCoV |
Shanghai Public Health Clinical Center |
NCT04261517 / Recruiting patients |
6-2-2020 / 31-12-2020 |
3 |
Chloroquine |
10000 participants in a prophylaxis study for COVID-19 |
University of Oxford |
NCT04303507 / Not yet recruiting |
May 2020 / May 2022 |
N/A |
Human immunoglobulin |
Pneumonia caused by 2019-nCoV with 80 participants |
Peking Union Medical College Hospital |
NCT04261426 / Not yet recruiting patients |
10-2-2020 / 30-06-2020 |
2 and 3 |
Remdesivir |
Severe respiratory infection caused by 2019-nCoV with 452 participants |
Capital Medical University |
NCT04257656 / Recruiting patients |
6-2-2020 / 31-05-2020 |
3 |
Remdesivir |
308 participants with mild/ moderate respiratory infection caused by 2019-nCoV |
Capital Medical University |
NCT04252664 / Recruiting patients |
05-02-2020 / 27-04-2020 |
3 |
Arbidol (umifenovir) |
Pneumonia caused by 2019-nCoV with 380 participants |
Jieming QU, Ruijin Hospital |
NCT04260594 / Not yet recruiting patients |
7-02-2020 / 30-12-2020 |
4 |
Arbidol or lopinavir-ritonavir or oseltamivir |
400 participants infected with 2019-nCoV |
Tongji Hospital |
NCT04255017 / Recruiting patients |
01-02-2020 / 01-07-2020 |
4 |
Arbidol or lopinavir-ritonavir |
125 participants infected with 2019-nCoV |
Guangzhou 8th People’s Hospital |
NCT04252885 / Recruiting patients. |
28-01-2020 / 31-07-2020 |
4 |
Darunavir-cobicistat combination |
Pneumonia caused by 2019-nCoV with 30 participants |
Shanghai Public Health Clinical Center |
NCT04252274 / Recruiting patients |
30-01-2020 / 31-12-2020 |
3 |
TCM combination with lopinavir-ritonavir, a-interferon via aerosol |
150 participants infected with 2019-nCoV |
Beijing 302 Hospital |
NCT04251871 / Recruiting patients |
22-01-2020 / 22-01-2021 |
N/A |
Recombinant human interferon α2β |
328 participants with COVID-19 |
Tongji Hospital |
NCT04293887 / Not yet recruiting |
01-03-2020 / 30-06-2020 |
1 |
Carrimycin or lopinavir-ritonavir or arbidol or chloroquine phosphate |
520 participants with COVID-19 |
Beijing YouAn Hospital |
NCT04286503 / Not yet recruiting |
23-02-2020 / 28/02-2021 |
4 |
Danoprevir-ritonavir and interferon inhalation or lopinavir-ritonavir or TCM plus interferon inhalation |
50 participants with pneumonia caused by 2019-nCoV |
The Ninth Hospital of Nanchang |
NCT04291729 / Recruiting |
14-02-2020 / 30-04-2020 |
4 |
Xiyanping or lopinavir-ritonavir-interferon inhalation |
384 participants with pneumonia caused by 2019-nCoV |
Jiangxi Qingfeng Pharmaceutical Co. Ltd. |
NCT04275388 / Not yet recruiting |
19-02-2020 / 14-12-2020 |
N/A |
Xiyanping combined with lopinavir-ritonavir |
80 participants with COVID-19 |
Jiangxi Qingfeng Pharmaceutical |
NCT04295551 / Not yet recruiting |
14-03-2020 / 14-04-2021 |
N/A |
Combinations of oseltamivir, favipiravir, and chloroquine |
80 participants with COVID-19 |
Rajavithi Hospital |
NCT04303299 / Not yet recruiting |
15-03-2020 / 30-11-2020 |
3 |
Thalidomide |
40 participants with COVID-19 |
First Affiliated Hospital of Wenzhou Medical University |
NCT04273581 / Not yet recruiting |
18-02-2020 / 30-05-2020 |
2 |
Thalidomide |
100 participants with pneumonia caused by 2019-nCoV |
First Affiliated Hospital of Wenzhou Medical University |
NCT04273529 / Not yet recruiting |
20-02-2020 / 30-06-2020 |
2 |
Vitamin C |
140 participants with severe pneumonia caused by 2019-nCoV |
ZhiYong Peng |
NCT04264533 / Recruiting |
14-02-2020 / 30-09-2020 |
2 |
Methylprednisolone |
80 participants infected with 2019-nCoV |
Peking Union Medical College Hospital |
NCT04244591 / Recruiting patients |
26-01-2020 / 25-12-2020 |
2 |
Pirfenidone |
294 participants with severe pneumonia caused by 2019-nCoV |
Huilan Zhang |
NCT04282902 / Recruiting |
04-02-2020 / 01-06-2020 |
3 |
Bromhexine hydrochloride |
60 participants with suspected and mild pneumonia caused by 2019-nCoV |
Second Affiliated Hospital of Wenzhou Medical University |
NCT04273763 / Enrolling by invitation |
16-02-2020 / 30-04-2020 |
N/A |
Bevacizumab |
20 participants with severe COVID-19 pneumonia |
Qilu Hospital of Shandong University |
NCT04275414 / Recruiting |
February 2020 / May 2020 |
2 and 3 |
Fingolimod |
30 participants with COVID-19 |
1° Affiliated Hospital of Wenzhou Medical University |
NCT04280588 / Recruiting |
22-02-2020 / 01-06-2020 |
2 |
COVID-19, coronavirus disease 2019; 2019-nCoV, novel coronavirus 2019; TCM, traditional Chinese medicine